ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0020

Citrullination Drives the Expression of Pro-fibrotic Genes in Rheumatoid Arthritis Fibroblast-like Cells

Peter Maloley, Evan Ryan, Nozima Aripova, Michael Duryee, Bryant England, Ted Mikuls and Geoffrey Thiele, University of Nebraska Medical Center, Omaha, NE

Meeting: ACR Convergence 2021

Keywords: citrullination, Fibroblasts, Synovial, Inflammation, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 6, 2021

Title: RA – Etiology & Pathogenesis Poster (0011–0045)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: The pathophysiology of rheumatoid arthritis (RA) is hallmarked by joint inflammation, thickening of the pannus, and resultant joint destruction. Within the synovial tissue, citrullinated antigens and malondialdehyde-acetaldehyde (MAA)-modified proteins co-localize, implicating a potential synergistic role in the induction of immune and pro-fibrotic responses. To further elucidate the mechanisms by which these modifications contribute to RA pathogenesis, we studied fibrotic gene expression by human fibroblast-like synoviocytes from RA patients (HFLS-RA) in response to stimulation with citrullinated and/or MAA-modified fibrinogen.

Methods: HFLS-RA cells were treated with native fibrinogen versus citrullinated and/or MAA-modified fibrinogen for 8 hours with sham treated HFLS-RA cells as reference, and mRNA was isolated. Expression of 763 genes was quantified using the NanoString® nCounter® Human Fibrosis Panel. Comparisons of gene expression across treatment groups were performed using differential expression analysis. Only genes with increased or decreased expression compared to untreated HFLS-RA cells were reported in the final results. Data was reported using log2 of normalized ratio with the sham group as reference.

Results: The gene responses of treated HFLS-RA cells were categorized based on their role in the fibrotic pathway (inflammation, initiation, modification, and proliferation) with many genes having influence on multiple pathways. Of the 763 genes analyzed, 58 demonstrated differential expression when exposed to modified antigen (Figure 1). Forty genes exhibited significantly increased expression when treated with citrullinated-fibrinogen alone compared to native unmodified fibrinogen (Figure 2). Of these 40 genes, four also demonstrated increased expression after treatment with fibrinogen co-modified with citrulline and MAA (Figure 3). One gene, CCL2 (inflammation), yielded increased gene expression in response to co-modified fibrinogen but not to citrullinated antigen alone (Figure 3). Treatment with MAA-modified fibrinogen alone did not generate any significant differential expression.

Conclusion: In this study, citrullinated fibrinogen augmented gene expression most conspicuously, whereas MAA-modification alone did not. Interestingly, co-modification did demonstrate a synergistic pro-fibrotic synovial response in one gene (CCL2) that was not seen with either single modification alone. Many of the genes identified have previously been shown to correlate with anti-citrullinated antibodies and RA disease activity, and thus, these post-translationally modified proteins may play a role in the development of fibrosis that contributes to joint pathology in RA. We would benefit from further elucidation of the synergistic role MAA and citrulline play and if that could be a target of diagnostic and/or therapeutic clinical practice.

Figure 1. Heat map (red = increased; blue = decreased) of significant genes expressed following 8-hour treatment of HFLS-RA cells with native fibrinogen (control), citrullinated fibrinogen, MAA-modified fibrinogen, or MAA-modified and citrullinated fibrinogen. Gene profiles were categorized into inflammation, initiation, modification, and proliferation. The heat map bar on the right is expressed as fold-change compared to control.

Figure 2. Genes that were significantly increased (red) or decreased (blue) by citrullinated fibrinogen were extracted from the heat maps and expressed as the log2 ratio compared to native fibrinogen (control). Gene profiles were categorized into inflammation, initiation, modification, and proliferation. Data is expressed as fold-change compared to control.

Figure 3. Genes that were significantly increased (red) or decreased (blue) by co-modification of fibrinogen with MAA and citrulline (Fib-MAA-CIT) were extracted from the heat maps and expressed as the log2 ratio compared to native fibrinogen (control). Data is expressed as fold-change compared to control.


Disclosures: P. Maloley, None; E. Ryan, None; N. Aripova, None; M. Duryee, None; B. England, Boehringer-Ingelheim, 2; T. Mikuls, Gilead Sciences, 2, Horizon, 2, 5, Pfizer Inc, 2, Sanofi, 2, Bristol-Myers Squibb, 2; G. Thiele, Regeneron, 6.

To cite this abstract in AMA style:

Maloley P, Ryan E, Aripova N, Duryee M, England B, Mikuls T, Thiele G. Citrullination Drives the Expression of Pro-fibrotic Genes in Rheumatoid Arthritis Fibroblast-like Cells [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/citrullination-drives-the-expression-of-pro-fibrotic-genes-in-rheumatoid-arthritis-fibroblast-like-cells/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/citrullination-drives-the-expression-of-pro-fibrotic-genes-in-rheumatoid-arthritis-fibroblast-like-cells/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology